非那雄胺联合M受体拮抗剂治疗前列腺增生合并膀胱过度活动症的疗效  

Clinical Efficacy of Finasteride Combined with M Receptor Antagonist in the Treatment of Patients with Prostatic Hyperplasia and Bladder Excessive Activity

作　　者：茅原申[1] 花豹 李文峰[1] 顾欣[1] 顾豫飞[1] 潘惟昕[1] 张士青[1] 陆超[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院泌尿科,上海200199

出　　处：《现代生物医学进展》2016年第31期6128-6131,共4页Progress in Modern Biomedicine

基　　金：上海市科学技术委员会科研计划项目(09411950100;1041195200)

摘　　要：目的:探讨非那雄胺联合M受体拮抗剂对前列腺增生合并膀胱过度活动症临床疗效的影响。方法:回顾性研究我院前列腺增生合并膀胱过度活动症的患者60例,随机分为实验组和对照组,每组30例。对照组患者给予M受体拮抗剂,实验组患者在对照组的基础上给予非那雄胺。观察并比较治疗前后两组患者国际前列腺症状评分(IPSS)、膀胱过度活动症评分(OABSS)、残余尿量、最大尿流率、尿急次数以及治疗期间不良反应。结果:与对照组相比,实验组患者IPSS及OABSS较低(P<0.05);残余尿量较少,最大尿流率较大,尿急次数较少(P<0.05);不良反应发生率较低(P<0.05)。结论:非那雄胺联合M受体拮抗剂能够降低前列腺增生合并膀胱过度活动症的不良反应发生率,提高临床疗效,值得在临床上推广应用。Objective： To investigate the clinical efficacy of finasteride combined with M receptor antagonist in the treatment of patients with prostatic hyperplasia and bladder excessive activity. Methods： Retrospective study a total of 60 patients with prostatic hyperplasia and bladder excessive activity from our hospital were collected and randomly divided into experiment group and control group with 30 cases in each group. Patients in the control group were treated by M receptor antagonist, patients in the experiment group were treated on the base of control group with finasteride. Compared the international prostate symptom score（IPSS）, bladder excessive activity symptom score（OABSS）, prostate volume, residual urine volume, maximal urinary flow rate and the number of urgency of the two groups before and after treatment, statistics the adverse reactions of the two groups occurred during treatment. Results： Compared with the control group, the IPSS and OABSS levels of the experiment group were lower（P〈0.05）; prostate volume was smaller（P〈0.05）;residual urine volume was less, maximal urinary flow rate was larger, the number of urgency was less（P〈0.05）; adverse reactions occurred rate was lower（P〈0.05）. Conclusion： Finasteride combined with M receptor antagonist in the treatment of patients with prostatic hyperplasia and bladder excessive activity can reduce the incidence of adverse reactions, improve the clinical efficacy, it is worth to be popularized in clinical application.

关 键 词：非那雄胺 M受体拮抗剂 前列腺增生 膀胱过度活动症 

分 类 号：R697.32[医药卫生—泌尿科学]